Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Sustained Clearance of Mansonella ozzardi Infection after Treatment with Ivermectin in the Brazilian Amazon

Full text
Author(s):
Basano, Sergio de Almeida [1, 2] ; Fontes, Gilberto [3] ; Medeiros, Jansen Fernandes [4] ; de Almeida Aranha Camargo, Juliana Souza [5] ; Souza Vera, Luana Janaina [5] ; Parente Araujo, Marcos Paulo [5] ; Pires Parente, Maira Santiago [5] ; Mattos Ferreira, Ricardo de Godoi [4] ; Barreto Crispim, Pedro di Tarique [6] ; Aranha Camargo, Luis Marcelo [1, 7]
Total Authors: 10
Affiliation:
[1] Dept Med, Fac Sao Lucas, Porto Velho, Rondonia - Brazil
[2] Secretaria Sande Estado Rondonia, Porto Velho, Rondonia - Brazil
[3] Univ Fed Sao Joao del Rei, Divinopolis, MG - Brazil
[4] Fiocruz Rondonia, Fundacao Oswaldo Cruz, Porto Velho, Rondonia - Brazil
[5] Fac Sao Lucas, Porto Velho, Rondonia - Brazil
[6] Univ Fed Rondonia, Porto Velho, Rondonia - Brazil
[7] Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biomed 5, Sao Paulo - Brazil
Total Affiliations: 7
Document type: Journal article
Source: American Journal of Tropical Medicine and Hygiene; v. 90, n. 6, p. 1170-1175, JUN 2014.
Web of Science Citations: 14
Abstract

Therapy for mansonelliasis is challenging because there is no standard drug recommended for its treatment. This non-randomized study was conducted to evaluate the effectiveness of a single dose of 0.15 mg/kg of ivermectin to reduce Mansonella ozzardi microfilaraemia in infected persons. A total of 74 patients were studied within the municipality of Labrea, which is located in Amazonas State, Brazil. The patients were treated with ivermectin after detection of the parasite by blood examination. Significant microfilaraemia reduction was observed and its residual effect was maintained for at least 12 months. There was no significant change in the laboratory blood count, hepatic metabolites, and nitrogen-bounding compound excreta dosage values that could compromise the use of this drug, demonstrating that ivermectin has a low toxicity level. (AU)

FAPESP's process: 08/10817-6 - Clinical trial with ivermectine for the treatment of Mansonella ozzardi infections
Grantee:Luís Marcelo Aranha Camargo
Support Opportunities: Regular Research Grants